This product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, targeting the GSDMA gene. The GSDMA knockout polyclonal cells provide a loss-of-function model to study gasdermin A-mediated biological processes. Through CRISPR/Cas9-mediated gene disruption, the GSDMA coding sequence is inactivated, enabling researchers to dissect the role of this pore-forming executor in pyroptosis and related cellular pathways.
HeLa cells are a widely utilized human cervical adenocarcinoma epithelial cell line, originally derived from Henrietta Lacks in 1951. This immortalized line is HPV18-positive, with p53 and Rb tumor suppressors inactivated by viral oncoproteins E6 and E7, respectively. HeLa cells serve as a robust model for studying cancer biology, gene function, and cellular signaling, and their epithelial origin makes them particularly relevant for investigating programs such as pyroptosis, which involves cell swelling and lysis.
GSDMA encodes gasdermin A, a key executor of pyroptotic cell death. Upon cleavage by upstream activators such as caspase-3, granzyme A, or granzyme B, the N-terminal fragment of GSDMA (GSDMA-N) is liberated and oligomerizes to form membrane pores. These pores permeabilize the plasma membrane, leading to cell swelling and lysis, and facilitate the release of damage-associated molecular patterns (DAMPs) including HMGB1, IL-1??, and LDH. GSDMA function is integrated within inflammasome and caspase signaling cascades, and it interacts with caspase-3 and GSDMB. Additionally, inflammatory cytokines like TGF-?? and TNF-?? can regulate GSDMA expression, thereby influencing pyroptotic sensitivity. Downstream consequences of pore formation include the secretion of pro-inflammatory mediators, linking GSDMA to epithelial defense, inflammation, and tumor suppression.
In the HeLa cell background, GSDMA knockout provides a powerful tool to investigate the role of pyroptosis in cervical adenocarcinoma biology. HeLa cells, with their defined HPV-driven immortalization and defective p53/Rb pathways, offer a cancer cell context in which gasdermin-mediated cell death may be subverted. Ablation of GSDMA allows researchers to assess its contribution to cell death resistance, inflammatory cytokine release, and potential tumor-suppressive functions. Given that GSDMA has been implicated in gastric cancer and inflammatory disorders, this knockout model enables dissection of its molecular interactions in an epithelial cancer setting, and may reveal dependencies on caspase-3 or granzyme-mediated pathways.
Typical applications of the GSDMA knockout HeLa polyclonal cells include the study of pyroptosis induction via caspase-3 activation or granzyme delivery, as well as investigation of inflammatory responses through IL-1?? ELISA and LDH release assays. These cells are suitable for phenotypic screening with phase-contrast microscopy to monitor cell swelling, flow cytometry for cell death quantification, and Western blotting to detect GSDMA cleavage. Co-immunoprecipitation can be employed to probe GSDMA interactions with caspase-3 or GSDMB. Moreover, the cells serve as a platform for drug screening targeting pyroptosis modulators, contributing to cancer therapy research. For further inquiries about this product, please contact Ascent Research.
